Evotec SE (EVO) Bundle
Ever wondered how new drugs are discovered and developed? Evotec SE (EVO), a global drug discovery and development company founded in 1993, stands at the forefront of this vital process. With a mission to discover and develop highly effective therapeutics, how exactly does Evotec operate and generate revenue in the complex world of pharmaceutical innovation, and what is its history? Dive in to explore Evotec's journey, its ownership structure, its mission, and its unique approach to making medicines that matter, especially given its €644.8 million revenue in 2023 and its collaborations with top pharmaceutical companies.
Evotec SE (EVO) History
Evotec's Founding Timeline
Year established
Evotec was established in 1993.
Original location
The company was originally located in Hamburg, Germany.
Founding team members
Evotec was founded by a team of scientists and entrepreneurs including Dr. Karsten Henco, Professor Dr. Klaus Breddin, and Dr. Ulrich Erhardt.
Initial capital/funding
The initial funding for Evotec came from a variety of sources, including venture capital and early-stage investors. While the exact amount isn't specified, it was enough to establish the company and begin its initial research and development activities.
Evotec's Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 1993 | Evotec was founded in Hamburg, Germany. | Established the company as a drug discovery firm. |
| 1999 | Evotec gets listed on the Frankfurt Stock Exchange. | Provided capital for expansion and increased visibility. |
| 2004 | Acquisition of Oxford Asymmetry International plc (OAI). | Expanded capabilities in medicinal chemistry and early-stage development. |
| 2008 | Acquired Renovis, Inc. | Strengthened position in neuroscience research. |
| 2010 | Launched compound management business line, EVOcells. | Diversified service offerings beyond drug discovery. |
| 2014 | Strategic alliance with Sanofi. | Enhanced drug discovery capabilities and pipeline. |
| 2016 | Acquisition of Cyprotex. | Expanded capabilities in ADME-Tox and preclinical services. |
| 2017 | Partnership with CRISPR Therapeutics. | Advanced gene editing technologies for drug discovery. |
| 2019 | Acquisition of Just Biotherapeutics. | Significantly expanded capabilities in biologics development and manufacturing. |
| 2020 | Evotec enters into a drug discovery partnership with Takeda. | Focuses on developing innovative therapeutics. |
| 2021 | Expanded partnership with Bristol Myers Squibb. | Further strengthened drug discovery and development efforts. |
| 2022 | Evotec faced a cyberattack. | The company took immediate action to contain, investigate, and remediate the incident. |
| 2023 | Evotec announces a new strategic partnership with Sandoz. | The collaboration aims to develop and manufacture biosimilars. |
Evotec's Transformative Moments
- Strategic Acquisitions: Evotec's acquisition strategy has been pivotal in expanding its service offerings and technological capabilities. The acquisitions of Oxford Asymmetry International (OAI), Renovis, Cyprotex, and Just Biotherapeutics each added new dimensions to Evotec's portfolio, enhancing its ability to offer comprehensive solutions across the drug discovery and development value chain.
- Key Partnerships: Strategic alliances with major pharmaceutical companies such as Sanofi, Bristol Myers Squibb, Takeda, and Sandoz have been transformative. These partnerships not only provided financial support but also validated Evotec's scientific expertise and technological platforms, leading to collaborative drug discovery programs and the development of innovative therapeutics.
- Focus on Innovation: Evotec's early adoption and integration of innovative technologies like high-throughput screening, genomics, and CRISPR gene editing have set it apart in the industry. These technological advancements have enabled Evotec to accelerate drug discovery processes, improve target validation, and develop more effective therapies.
- Expansion into Biologics: The acquisition of Just Biotherapeutics marked a significant strategic shift for Evotec, enabling the company to expand its services into biologics development and manufacturing. This move positioned Evotec to capitalize on the growing demand for biologic drugs and offer integrated solutions for both small molecule and large molecule therapeutics.
To understand more about the investors, read this interesting article: Exploring Evotec SE (EVO) Investor Profile: Who’s Buying and Why?
Evotec SE (EVO) Ownership Structure
Evotec SE operates as a publicly listed company with a diverse shareholder base, including institutional and retail investors.
Evotec's Current Status
Evotec SE is a publicly traded company, meaning its shares are available for purchase on the stock market. It is listed on the Frankfurt Stock Exchange under the ticker symbol EVO. This allows a wide range of investors to own a part of the company.
Evotec's Ownership Breakdown
As a publicly traded company, Evotec's ownership is distributed among various shareholders. While specific real-time ownership percentages fluctuate, here's a general overview based on the latest available information:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | ~60-70% | These are typically investment funds, pension funds, and other large financial institutions. |
| Retail Investors | ~20-30% | Individual investors who hold smaller stakes in the company. |
| Other | ~10% | May include company insiders, employees with stock options, or other strategic investors. |
Evotec's Leadership
The leadership team is crucial for guiding the strategic direction of Evotec. As of April 2025, key figures include:
- Dr. Christian Wojczewski: Chief Executive Officer
- Dr. Laetitia Rouxel: Chief Business Officer
- Enno Spillner: Chief Financial Officer
- Dr. Matthias Evers: Chief Operating Officer
These individuals, along with other members of the management board, are responsible for the overall performance and strategic initiatives. The Supervisory Board oversees and advises the management board.
To gain more insight into the company's guiding principles, explore Mission Statement, Vision, & Core Values of Evotec SE (EVO).
Evotec SE (EVO) Mission and Values
Evotec's mission is to discover and develop innovative solutions for unmet medical needs. The company is committed to creating value for its stakeholders through scientific excellence, strategic partnerships, and operational efficiency.
Evotec SE's Core Purpose
Official mission statement
Evotec's official mission statement is: 'We want to be the world-leading company in the discovery and development of novel therapeutics by building on our world-class science, technology and people.'
- To accelerate the discovery and development of new medicines.
- To provide innovative solutions and services to the pharmaceutical and biotechnology industries.
- To improve the lives of patients worldwide.
Vision statement
Evotec envisions becoming a world-leading company in the discovery and development of novel therapeutics. This involves:
- Building on world-class science, technology, and people.
- Expanding its network of strategic partnerships.
- Delivering innovative solutions to address unmet medical needs.
Company slogan/tagline
Evotec's tagline, 'Data-driven drug discovery. Partnering to cure,' encapsulates its approach to drug discovery and development, highlighting:
- The use of data and technology to drive innovation.
- The importance of collaboration in achieving its goals.
- The ultimate aim of curing diseases and improving patient outcomes.
To learn more about Evotec, check out: Exploring Evotec SE (EVO) Investor Profile: Who’s Buying and Why?
Evotec SE (EVO) How It Works
Evotec SE operates as a drug discovery and development company, providing solutions to pharmaceutical and biotechnology companies, academic institutions, and other organizations in the healthcare industry.
Evotec's Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Drug Discovery Solutions | Pharmaceutical and biotechnology companies | Integrated drug discovery platforms, including target identification, lead generation, and preclinical development. |
| Development Services | Pharmaceutical and biotechnology companies | Clinical development support, including formulation development, manufacturing, and clinical trial management. |
| Just - Evotec Biologics | Biopharmaceutical companies | Biologics development and manufacturing services, focusing on protein therapeutics. |
| Data Science Solutions | Pharmaceutical and biotechnology companies | Utilizing data analytics and artificial intelligence to accelerate drug discovery and development processes. |
Evotec's Operational Framework
Evotec's operational framework is built around providing integrated solutions across the drug discovery and development value chain. Key aspects include:
- Integrated Platforms: Evotec offers comprehensive, integrated platforms that cover the entire drug discovery process, from target identification to preclinical development.
- Strategic Collaborations: The company engages in strategic collaborations with pharmaceutical and biotechnology companies, academic institutions, and other research organizations to advance drug discovery and development programs.
- Data-Driven Approach: Evotec leverages data analytics, artificial intelligence, and machine learning to enhance decision-making and accelerate drug discovery timelines.
- Global Network: With facilities and partnerships across Europe, North America, and Asia, Evotec operates a global network to serve its clients and partners.
Evotec's Strategic Advantages
Evotec's success and competitive positioning are driven by several strategic advantages:
- Comprehensive Service Offering: Evotec provides a broad range of services spanning the entire drug discovery and development process, making it a one-stop-shop for its clients.
- Technological Innovation: The company invests heavily in technology and innovation, including advanced screening technologies, data analytics, and AI-driven drug discovery platforms.
- Strong Partnerships: Evotec has established strong partnerships with leading pharmaceutical and biotechnology companies, providing access to valuable resources and expertise.
- Experienced Management Team: Evotec is led by an experienced management team with a proven track record in the pharmaceutical and biotechnology industries.
- Focus on Innovation: A strong emphasis on innovation enables Evotec to stay at the forefront of drug discovery and development, offering cutting-edge solutions to its clients.
To gain more insights into the investors profile, read this article: Exploring Evotec SE (EVO) Investor Profile: Who’s Buying and Why?
Evotec SE (EVO) How It Makes Money
Evotec SE primarily generates revenue by providing drug discovery and development services to pharmaceutical and biotechnology companies. These services span the entire drug development process, from target identification to clinical development.
Evotec SE's Revenue Breakdown
Evotec's revenue is derived from a mix of research and development services and milestone payments tied to the progress of partnered drug development programs.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Fee-for-Service Revenue (R&D Services) | Approximately 60% - 70% | Increasing, driven by demand for outsourced R&D. |
| Milestone Payments & Royalties | Approximately 30% - 40% | Variable, dependent on clinical and regulatory success of partnered programs. |
Evotec SE's Business Economics
Evotec's business economics are shaped by several key factors:
- Pricing Strategy: Evotec employs a tiered pricing strategy for its services, reflecting the complexity and expertise required for each project. Prices are determined based on factors such as the scope of work, the scientific expertise needed, and the duration of the project.
- Cost Structure: A significant portion of Evotec's costs are related to research and development activities, including personnel, laboratory supplies, and equipment. Efficiency in managing these costs is crucial for maintaining profitability.
- Partnerships: Strategic alliances with pharmaceutical and biotechnology companies are vital. These partnerships not only provide revenue but also contribute to the long-term growth and sustainability of Evotec's business model.
- Market Dynamics: The demand for outsourced drug discovery services is influenced by trends in the pharmaceutical and biotechnology industries, such as the increasing focus on specialized research and the need for cost-effective drug development solutions.
Evotec SE's Financial Performance
Key aspects of Evotec's financial performance include:
- Revenue Growth: Evotec has demonstrated consistent revenue growth, driven by increasing demand for its services and successful execution of its business strategy. For example, in 2024, Evotec reported revenue of €864.5 million, marking a 6% increase compared to 2023.
- Profitability: While revenue growth is important, profitability is equally critical. Evotec's adjusted EBITDA reached €115.4 million in 2024, although this was lower than the €123.4 million reported in 2023.
- R&D Investment: Evotec continues to invest heavily in research and development to expand its service offerings and maintain a competitive edge. In 2024, the company's R&D expenses totaled €68.3 million.
- Order Backlog: A strong order backlog provides visibility into future revenue streams and indicates the demand for Evotec's services. As of 2024, Evotec's order backlog stood at €877.2 million.
To gain more insight into Evotec SE's mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Evotec SE (EVO).
Evotec SE (EVO) Market Position & Future Outlook
Evotec SE is strategically positioned to capitalize on the growing demand for innovative drug discovery solutions, holding a strong position in the pharmaceutical and biotechnology industries. As of April 2025, the company's future outlook appears promising, driven by its robust pipeline, strategic collaborations, and expansion into new therapeutic areas.
Competitive Landscape
The pharmaceutical and biotechnology industries are highly competitive. Here's how Evotec stacks up against some of its key competitors:
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Evotec SE | Approximately 3-5% in the global drug discovery services market | Strong expertise in integrated drug discovery platforms and long-term strategic partnerships with major pharmaceutical companies. |
| Charles River Laboratories | Approximately 7-9% | Extensive portfolio of preclinical and clinical laboratory services and a broad global presence. |
| WuXi AppTec | Approximately 10-12% | Large-scale research and manufacturing capabilities, particularly in Asia, offering cost-effective solutions. |
Opportunities & Challenges
Evotec faces a dynamic landscape of opportunities and risks that will shape its future trajectory.
| Opportunities | Risks |
|---|---|
| Expanding Strategic Collaborations: Forming new partnerships with pharmaceutical and biotech companies to broaden drug discovery capabilities and access diverse therapeutic areas. | Intense Competition: Facing increasing competition from other CROs and pharmaceutical companies with in-house discovery capabilities, potentially impacting market share and profitability. |
| Technological Advancements: Leveraging AI, machine learning, and advanced screening technologies to accelerate drug discovery processes and improve success rates. | Regulatory Hurdles: Navigating complex and evolving regulatory landscapes, which could delay drug development timelines and increase compliance costs. |
| Personalized Medicine: Capitalizing on the growing trend of personalized medicine by developing targeted therapies and diagnostics tailored to individual patient needs. | Economic Downturns: Economic recessions or financial crises could reduce R&D spending by pharmaceutical companies, affecting demand for Evotec's services. |
Industry Position
Evotec has solidified its position as a key player in the drug discovery and development space through several strategic initiatives:
- Strategic Partnerships: Evotec has fostered long-term collaborations with major pharmaceutical companies, enhancing its reputation and market reach.
- Technological Innovation: The company's focus on integrating cutting-edge technologies like AI and machine learning into its drug discovery platforms provides a competitive edge.
- Expansion into New Modalities: Evotec is expanding its capabilities in novel therapeutic modalities, positioning itself to capture emerging market opportunities.
To gain more insights into the investor perspective, explore: Exploring Evotec SE (EVO) Investor Profile: Who’s Buying and Why?
Evotec SE (EVO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.